Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

364.20GBp
20 Jun 2018
Change (% chg)

6.20 (+1.73%)
Prev Close
358.00
Open
361.40
Day's High
366.20
Day's Low
356.40
Volume
6,850,760
Avg. Vol
2,524,989
52-wk High
504.60
52-wk Low
246.50

Latest Key Developments (Source: Significant Developments)

Indivior Enters Into Settlement With Par Pharmaceutical in Patent Infringement Case
Monday, 14 May 2018 

May 14 (Reuters) - Indivior PLC ::INDIVIOR SETTLEMENT WITH PAR PHARMACEUTICAL.INDIVIOR ENTERS INTO SETTLEMENT WITH PAR PHARMACEUTICAL IN PATENT INFRINGEMENT CASE.SETTLEMENT RESOLVING PATENT LITIGATION RELATED TO SUBOXONE (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM.SETTLEMENT PERMITS PAR TO BEGIN SELLING GENERIC VERSION OF SUBOXONEFILM ON JAN 1, 2023, OR EARLIER UNDER CERTAIN CIRCUMSTANCES.  Full Article

‍Indivior Says Enters Into License Agreement For C4x Discovery's OX1 Antagonist Program​
Thursday, 29 Mar 2018 

March 29 (Reuters) - Indivior Plc ::‍INDIVIOR ENTERS INTO AN EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR C4X DISCOVERY'S OREXIN-1 (OX1) ANTAGONIST PROGRAM​.‍INDIVIOR UK LIMITED AND C4X DISCOVERY HOLDINGS PLC ENTERED INTO A LICENSE AGREEMENT​.INDIVIOR - ‍UNDER AGREEMENT, INDIVIOR UK OBTAINED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE C4X'S ORAL OREXIN-1 RECEPTOR ANTAGONIST PROGRAM​.INDIVIOR - ‍INDIVIOR UK WILL MAKE AN UPFRONT PAYMENT TO C4X OF $10 MILLION WITH POTENTIAL MILESTONE PAYMENTS TO C4X THAT COULD TOTAL $284 MILLION OVER TIME​.  Full Article

Addex and Indivior Sign Strategic Partnership
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - ADDEX THERAPEUTICS LTD ::REG-ADDEX AND INDIVIOR SIGN STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF GABAB PAMS AS ADDICTION TREATMENTS.UNDER TERMS OF AGREEMENT, ADDEX WILL RECEIVE $5 MILLION UPFRONT.UNDER TERMS OF AGREEMENT WILL RECEIVE $4 MILLION OF COMMITTED RESEARCH FUNDING OVER NEXT TWO YEARS.TO RECEIVE $330 MILLION OF POTENTIAL DEVELOPMENT.WILL RECEIVE REGULATORY AND COMMERCIALIZATION MILESTONES AND TIERED ROYALTIES UP TO DOUBLE-DIGIT.  Full Article

‍Indivior Says Repricing And Maturity Extension Of Term Loan Facilities
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - INDIVIOR PLC ::‍INDIVIOR ANNOUNCES REPRICING AND MATURITY EXTENSION OF TERM LOAN FACILITIES AND REPLACEMENT OF CREDIT FACILITY​.‍ENTERED AMENDMENT WITH VARIOUS LENDERS TO PROVIDE REPLACEMENT TERM LOAN FACILITIES IN AN AGGREGATE PRINCIPAL AMOUNT OF APPROXIMATELY $484 MILLION​.‍NEW TERM LOAN FACILITIES REDUCE GROUP'S INTEREST COUPON TO LIBOR PLUS 4.50% FROM LIBOR PLUS 6.00 PERCENT​.  Full Article

Indivior Announces NDA Acceptance Of RBP-7000 Risperidone Monthly Depot
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Indivior Plc ::INDIVIOR ANNOUNCES NDA ACCEPTANCE OF RBP-7000 RISPERIDONE MONTHLY DEPOT.FDA HAS SET A PDUFA TARGET ACTION DATE OF JULY 28, 2018.  Full Article

Indivior says Q3 net revenue $‍275​ mln vs. $268 mln
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Indivior Plc ::Q3 NET REVENUE $‍275​ MILLION VERSUS $268 MILLION A YEAR AGO.FY 2017 REVENUE AND NET INCOME GUIDANCE RECONFIRMED​.Q3 NET PROFIT $‍50 MILLION VERSUS LOSS OF $149 MILLION A YEAR AGO.SUBOXONE FILM MARKET SHARE AVERAGED 58 PCT IN YTD 2017 (YTD 2016: 61%).‍FINALIZING LAUNCH PLANS OF RBP-6000, WORKING WITH 3RD-PARTY MANUFACTURING PARTNERS TO APPROPRIATE DELIVERY TO ENABLE TARGET LAUNCH IN Q1 2018​.  Full Article

FDA committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Indivior PLC :FDA advisory committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder.Indivior PLC - ‍FDA has set a prescription drug user fee act (PDUFA) target action date of November 30, 2017​.  Full Article

Old Mutual cuts stake in Indivior to 4.36 pct
Monday, 9 Oct 2017 

Oct 9 (Reuters) - Indivior Plc :OLD MUTUAL CUTS STAKE IN INDIVIOR TO 4.36 PERCENT FROM 7.01 PERCENT STAKE EARLIER- FILING‍​.  Full Article

Indivior says submitted NDA to FDA for schizophrenia​ treatment
Monday, 2 Oct 2017 

Oct 2 (Reuters) - Indivior Plc ::U.S. UNIT SUBMITTED NDA TO FDA ON SEPT. 28, TO SEEK MARKETING APPROVAL FOR RBP-7000, INDIVIOR'S TREATMENT OF SCHIZOPHRENIA​.  Full Article

Indivior to defend its position in U.S. anticompetitive practices lawsuit
Friday, 23 Sep 2016 

Indivior Plc : Indivior notified of civil complaint filed by State Attorneys General . Notified thirty-five U.S. States and District of Columbia filed a civil complaint alleging violations of state and federal antitrust and consumer protection laws .Company intends to continue to vigorously defend its position.  Full Article

Indivior shares dive after Dr Reddy's gets FDA approval for generic

Britain's Indivior fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue.